Cargando…

Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer

BACKGROUND: The mammalian target of rapamycin inhibitor everolimus is approved as an antitumor agent in advanced estrogen receptor-positive breast cancer. Surrogate bone marker data from clinical trials suggest effects on bone metabolism, but the mode of action of everolimus in bone biology remains...

Descripción completa

Detalles Bibliográficos
Autores principales:	Browne, Andrew J., Kubasch, Marie L., Göbel, Andy, Hadji, Peyman, Chen, David, Rauner, Martina, Stölzel, Friedrich, Hofbauer, Lorenz C., Rachner, Tilman D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5551016/ https://www.ncbi.nlm.nih.gov/pubmed/28793923 http://dx.doi.org/10.1186/s13058-017-0885-7

Ejemplares similares

p38 MAPK regulates the Wnt inhibitor Dickkopf-1 in osteotropic prostate cancer cells
por: Browne, A J, et al.
Publicado: (2016)

Zoledronic acid and atorvastatin inhibit αvβ3-mediated adhesion of breast cancer cells
por: Wilke, Maria, et al.
Publicado: (2014)

Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells
por: Göbel, Andy, et al.
Publicado: (2019)

Targeting syndecan-1 in breast cancer inhibits osteoclast functions through up-regulation of osteoprotegerin
por: Benad-Mehner, Peggy, et al.
Publicado: (2013)

Regulation of VEGF by mevalonate pathway inhibition in breast cancer
por: Rachner, Tilman D., et al.
Publicado: (2013)

Mice lacking DKK1 in T cells exhibit high bone mass and are protected from estrogen-deficiency-induced bone loss
por: Lehmann, Juliane, et al.
Publicado: (2021)

Dickkopf-1 is regulated by the mevalonate pathway in breast cancer
por: Rachner, Tilman D, et al.
Publicado: (2014)

Skeletal endocrinology: where evolutionary advantage meets disease
por: Jaschke, Nikolai, et al.
Publicado: (2021)

High serum levels of Dickkopf-1 are associated with a poor prognosis in prostate cancer patients
por: Rachner, Tilman D, et al.
Publicado: (2014)

Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients
por: Göbel, Andy, et al.
Publicado: (2019)

The Role of Inflammation in Breast and Prostate Cancer Metastasis to Bone
por: Göbel, Andy, et al.
Publicado: (2021)

RANKL/OPG in Breast Cancer — Extending Its Territory to BRCA Mutation Carriers
por: Rachner, Tilman D., et al.
Publicado: (2015)

From bone to breast and back - the bone cytokine RANKL and breast cancer
por: Hofbauer, Lorenz C, et al.
Publicado: (2011)

Soluble Neuropilin-1 is an independent marker of poor prognosis in early breast cancer
por: Rachner, Tilman D., et al.
Publicado: (2021)

Fatal attraction: why breast cancer cells home to bone
por: Hofbauer, Lorenz C, et al.
Publicado: (2008)

Targeting Bone Metabolism in Patients with Advanced Prostate Cancer: Current Options and Controversies
por: Todenhöfer, Tilman, et al.
Publicado: (2015)

Role of WNT5A receptors FZD5 and RYK in prostate cancer cells
por: Thiele, Stefanie, et al.
Publicado: (2018)

The Impact of Immune System in Regulating Bone Metastasis Formation by Osteotropic Tumors
por: D'Amico, Lucia, et al.
Publicado: (2015)

Decoding Single Cell Morphology in Osteotropic Breast Cancer Cells for Dissecting Their Migratory, Molecular and Biophysical Heterogeneity
por: Bemmerlein, Lila, et al.
Publicado: (2022)

Deconstructing cellular senescence in bone and beyond
por: Hofbauer, Lorenz C., et al.
Publicado: (2023)

Clinical impact of soluble Neuropilin-1 in ovarian cancer patients and its association with its circulating ligands of the HGF/c-MET axis
por: Klotz, Daniel Martin, et al.
Publicado: (2022)

The Bone Morphogenetic Protein Pathway: The Osteoclastic Perspective
por: Lademann, Franziska, et al.
Publicado: (2020)

Effects of adipocyte-specific Dkk1 deletion on bone homeostasis and obesity-induced bone loss in male mice
por: Daamouch, Souad, et al.
Publicado: (2023)

MicroRNA and Diabetic Bone Disease
por: Daamouch, Souad, et al.
Publicado: (2022)

Dickkopf1 fuels inflammatory cytokine responses
por: Jaschke, Nikolai P., et al.
Publicado: (2022)

Synthesis and Biological Evaluation of a New Polymeric Conjugate and Nanocarrier with Osteotropic Properties
por: Pignatello, Rosario, et al.
Publicado: (2012)

Contributions of Dickkopf‐1 to Obesity‐Induced Bone Loss and Marrow Adiposity
por: Colditz, Juliane, et al.
Publicado: (2020)

Dataset for the proteomic inventory and quantitative analysis of the breast cancer hypoxic secretome associated with osteotropism
por: Cox, Thomas R., et al.
Publicado: (2015)

Luspatercept mitigates bone loss driven by myelodysplastic neoplasms and estrogen-deficiency in mice
por: Weidner, Heike, et al.
Publicado: (2022)

Irisin and Bone in Sickness and in Health: A Narrative Review of the Literature
por: Tsourdi, Elena, et al.
Publicado: (2022)

Low Bone Turnover Due to Hypothyroidism or Anti-Resorptive Treatment Does Not Affect Whole-Body Glucose Homeostasis in Male Mice
por: Lademann, Franziska, et al.
Publicado: (2022)

Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties
por: Picke, Ann-Kristin, et al.
Publicado: (2019)

TRAF2 in osteotropic breast cancer cells enhances skeletal tumour growth and promotes osteolysis
por: Peramuhendige, Prabha, et al.
Publicado: (2018)

Osteotropism of neuroendocrine tumors: role of the CXCL12/CXCR4 pathway in promoting EMT in vitro
por: Cives, Mauro, et al.
Publicado: (2017)

Loss of Dkk-1 in Osteocytes Mitigates Alveolar Bone Loss in Mice With Periodontitis
por: Goes, Paula, et al.
Publicado: (2019)

CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer
por: Zoni, E, et al.
Publicado: (2017)

Farnesoid X receptor as marker of osteotropism of breast cancers through its role in the osteomimetism of tumor cells
por: Absil, L., et al.
Publicado: (2020)

Epo/EpoR signaling in osteoprogenitor cells is essential for bone homeostasis and Epo-induced bone loss
por: Rauner, Martina, et al.
Publicado: (2021)

SUN-LB65 Circulating Micrornas Linked to Bone Metabolism Are Affected by Sequential Anti Osteoporotic Treatment in Postmenopausal Osteoporosis
por: Yavropoulou, Maria, et al.
Publicado: (2020)

Effect of Anti-Osteoporotic Treatments on Circulating and Bone MicroRNA Patterns in Osteopenic ZDF Rats
por: Carro Vázquez, David, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_78f0nl7sobt7oat9rbi8l50q7j